Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | RORC | P51449 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199692 | 0.89 | MAPT (0.82) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL7722834 | 0.87 | MAPT (0.81) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL7929907 | 0.87 | MAPT (0.79) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1593423 | 0.87 | MAPT (0.79) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL3727171 | 0.86 | NPY5R (0.64) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL4725254 | 0.86 | MAPT (0.85) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL7722815 | 0.85 | NPSR1 (1.00) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL4728842 | 0.85 | NPY5R (0.83) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL4728393 | 0.85 | KDM4E (0.83) | MAPTKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1593514 | 0.85 | KDM4E (0.83) | MAPTKDM4ELMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1567525-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MAPT 4833/4885KDM4E 2975/4885LMNA 2835/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MAPT 4829/4885KDM4E 2949/4885LMNA 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.